Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

Abstract

Background Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed that CMA improves the AD-associated histological parameters in the animals. CMA promotes mitochondrial fatty acid uptake from the cytosol, facilitates fatty acid oxidation in the mitochondria, and alleviates oxidative stress. Methods Here, we designed a randomised, double-blinded, placebo-controlled phase-II clinical trial and studied the effect of CMA administration on the global metabolism of AD patients. One-dose CMA included 12.35 g L-serine (61.75%), 1 g nicotinamide riboside (5%), 2.55 g N-acetyl-L-cysteine (12.75%), and 3.73 g L-carnitine tartrate (18.65%). AD patients received one dose of CMA or placebo daily during the first 28 days and twice daily between day 28 and day 84. The primary endpoint was the difference in the cognitive function and daily living activity scores between the placebo and the treatment arms. The secondary aim of this study was to evaluate the safety and tolerability of CMA. A comprehensive plasma metabolome and proteome analysis was also performed to evaluate the efficacy of the CMA in AD patients. Results We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores. Improved cognitive functions in AD patients were supported by the relevant alterations in the hippocampal volumes and cortical thickness based on imaging analysis. Moreover, the plasma levels of proteins and metabolites associated with NAD + and glutathione metabolism were significantly improved after CMA treatment. Conclusion Our results indicate that treatment of AD patients with CMA can lead to enhanced cognitive functions and improved clinical parameters associated with phenomics, metabolomics, proteomics and imaging analysis. Trial registration ClinicalTrials.gov NCT04044131 Registered 17 July 2019, https://clinicaltrials.gov/ct2/show/NCT04044131

Obesity Facilitates Sex-Specific Improvement In Cognition And Neuronal Function In A Rat Model Of Alzheimer’s Disease

“…Metabolic reprogramming has been experimented both preclinically and in clinical trials: In streptozotocin-induced AD-like female rats, a panel of orally administered metabolic activators yielded beneficial effects on neurodegeneration (Turkez et al, 2023). The same metabolic activators also improved cognitive readouts in a Phase II clinical trial consisting of 69 AD patients (Yulug et al, 2023). Targeting metabolic pathways through reprogramming is thus a feasible approach for AD treatment.…”

The functional role of the pulvinar in discriminating between objective and subjective cognitive impairment in major depressive disorder

“…The pulvinar, for instance, differs from other well‐known cognitive regions such as the hippocampus. However, recent research, including investigation by ourselves, 40 , 56 suggests that this unique region with its diverse cortical connections and gatekeeper function also plays a critical role in cognitive impairment in neurodegenerative diseases. 51 In terms of cognition, these results, together with our current findings, are especially valuable in the light of growing evidence of an increased risk of dementia in MDD, irrespective of whether any subjective evidence is available for those cognitive symptoms.…”

Gut microbiota-driven metabolic alterations reveal gut–brain communication in Alzheimer’s disease model mice

“…Furthermore, we investigated the associations between the identified metabolites and cognitive functions in humans using publicly accessible data ( Figure 6 ). 37 Notably, the level of deoxycholate (a derivative of DCA) was correlated with Mini-Mental State Examination (MMSE) score ( R 2 = 0.03, p = 0.026), indicating that DCA has a potential cognitive-enhancing effect in humans. Furthermore, deoxycholate level was correlated with insulin level ( R 2 = 0.16, p < 0.001), although we did not observe a significant correlation between insulin and cognitive functions in humans (Supplementary Figure S5).…”